1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Madopar (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Madopar (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Madopar is a combination therapy of levodopa with benserazide hydrochloride, a dopamine decarboxylase inhibitor, developed and marketed by Roche. It is used to treat the signs and symptoms of Parkinson’s disease, but does not treat the underlying condition. Similar to other levodopa therapies, over time, patients may show reduced responsiveness to Madopar.

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Madopar including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Madopar for the top seven countries from 2012 to 2022.
- Sales information covered for France, Germany, Italy, Spain, the UK, Japan and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Madopar performance
- Obtain sales forecast for Madopar from 2012-2022 in the top seven countries (France, Germany, Italy, Spain, the UK, Japan and Brazil).

Table Of Contents

Madopar (Parkinson’s Disease) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 20
4.1 Overview 20
4.1.1 Diagnosis - The UK Brain Bank Criteria 20
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.2 Treatment Synopsis 24
4.2.1 Dopaminergic Therapy Classes 24
4.2.2 Treatment of Parkinson's Disease by Stage 26
4.2.3 Other Treatment Options 29
4.3 Parkinson's Disease Assessment Scales 29
4.3.1 Unified Parkinson's Disease Rating Scale (UPDRS) 30
4.3.2 Hoehn and Yahr Clinical Staging 32
4.3.3 Other Clinical Assessments 33
5 Competitive Assessment 34
5.1 Overview 34
5.2 Strategic Competitor Assessment 36
5.3 Product Profiles - Levodopa Combination Therapy 38
6 Madopar (levodopa/benserazide) 39
6.1 Overview 39
6.2 Efficacy 40
6.3 Safety 41
6.4 SWOT Analysis 42
6.5 Forecast 42
7 Appendix 45
7.1 Bibliography 45
7.2 Abbreviations 49
7.3 Methodology 52
7.4 Forecasting Methodology 52
7.4.1 Diagnosed Parkinson's Disease Patients 52
7.4.2 Percent Drug-Treated Patients 53
7.4.3 General Pricing Assumptions 53
7.4.4 Compliance Assumptions 54
7.4.5 Individual Drug Assumptions 55
7.4.6 Generic Erosion 56
7.5 Physicians and Specialists Included in this Study 57
7.6 About the Authors 59
7.6.1 Author 59
7.6.2 Global Head of Healthcare 60
7.7 About GlobalData 61
7.8 Disclaimer 61

1.1 List of Tables

Table 1: Symptoms of Parkinson's Disease 19
Table 2: UK Brain Bank Diagnostic Criteria 21
Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease 22
Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014 23
Table 5: Dopaminergic Therapy in Parkinson's Disease 26
Table 6: UPDRS Clinical Assessment of Disease Severity 31
Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials 33
Table 8: Treatment of Motor Symptoms in Parkinson's Disease 35
Table 9: Leading Treatments for Parkinson's Disease, 2014 37
Table 10: Product Profile - Madopar 40
Table 11: Madopar SWOT Analysis, 2014 42
Table 12: Global Sales Forecasts ($m) for Madopar, 2012-2022 43
Table 13: Global Sales Forecasts ($m) for Madopar CR, 2012-2022 44

1.2 List of Figures

Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes 25
Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.